PRLD241018C5000
- 1.20
- 0.000.00%
Prelude Therapeutics Newsroom
H.C. Wainwright Upgrades Prelude Therapeutics(PRLD.US) to Buy Rating, Maintains Target Price $5
Prelude Therapeutics Price Target Maintained With a $7.00/Share by JMP Securities
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
H.C. Wainwright Maintains Prelude Therapeutics(PRLD.US) With Hold Rating, Maintains Target Price $5
Prelude Therapeutics (PRLD) Gets a Sell From Barclays
Buy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial Position
JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Maintains Target Price $7
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $4
Prelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell Rating
H.C. Wainwright Maintains Prelude Therapeutics(PRLD.US) With Hold Rating, Maintains Target Price $5
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $3
Hold Rating on Prelude Therapeutics Pending Phase 1 Results of PRT3789
Prelude Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Neutral on Prelude Therapeutics, Maintains $5 Price Target
Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $4
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Maintains Target Price $3
Barclays Reaffirms Their Sell Rating on Prelude Therapeutics (PRLD)
Buy Rating Affirmed for Prelude Therapeutics on Strong Pipeline and Financial Position
Barclays Cuts Prelude to Underweight, Cites Lack of Near-term Catalysts